慢性功能性便秘患者对假电的安慰剂反应:二次分析
Zhiyi Xiong1, Peihong Ma1, Haoran Zhang2
1International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.
Neurogastroenterology and motility
|February 16, 2024
概括
电针对慢性便秘显示出适度的安慰剂反应. 基线肠道排便频率影响了假针的有效性,这表明它适合作为临床试验中的对照.
科学领域:
- 胃肠病学 胃肠病学
- 综合医学是一个整体的医学.
- 临床试验 临床试验
背景情况:
- 慢性严重功能性便秘需要创新的治疗方法.
- 针是一种潜在的治疗方法,但可能引起显著的安慰剂效应.
- 调查安慰剂反应的大小和影响性因素在便秘的电治疗是至关重要的.
研究的目的:
- 量化功能性便秘患者对电的安慰剂反应.
- 为了确定可能影响假装电对安慰剂反应的因素.
主要方法:
- 一项多中心随机试验的二次分析,该试验涉及假电针 (在非针点进行8周的表面针).
- 使用三个标准评估安慰剂反应率:每周完全自发排便 (CSBMs/week),整体CSBM和持续的CSBM.
- 使用后勤回归来确定影响安慰剂反应的因素.
主要成果:
- 在三个标准中,安慰剂反应率分别为10.58%,9.46%和9.09%.
- 具有更高基线频率的CSBMs/周的患者更有可能对假电做出反应.
- 在那些在基线时每周>1个CSBM的人群中,标准的响应率在22.22%至30.16%之间.
结论:
- 电在治疗功能性便秘方面没有显著的安慰剂反应.
- 基线CSBM频率似乎可以缓解假电对安慰剂的反应.
- 表面针假针是慢性便秘临床试验的合适控制方法.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252


